证券代码：600222 证券简称：太龙药业 公告编号：临 2023-049 河南太龙药业股份有限公司 二、监事会会议审议情况 （一）、审议通过《关于<河南太龙药业股份有限公司第四期员工 持股计划（草案）>及其摘要的议案》 监事会认为： （1）公司本期员工持股计划符合《公司法》、《证券法》、《关于 上市公司实施员工持股计划试点的指导意见》等法律、法规、规范性 文件和《公司章程》的规定，不存在禁止实施员工持股计划的情形； 第九届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 河南太龙药业股份有限公司（以下简称"公司"）第九届监事会第 十三次会议于 2023 年 10 月 17 日在公司一楼会议室以现场会议的方 式召开。会议通知已于 2023 年 10 月 12 日送达各位监事。本次会议 应出席监事 3 人，实际出席监事 3 人。会议由监事会主席张志贤先生 召集并主持。会议的召集、召开及表决程序符合有关法律、法规和《公 司章程》的规定，所作决议合法有效。 （2）公司实施员工持股计划 ...

河南太龙药业股份有限公司独立董事 关于第九届董事会第十八次会议审议相关事项的独立意见 作为河南太龙药业股份有限公司(以下简称"公司")的独立董事， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人 民共和国证券法》（以下简称《证券法》）、《上市公司独立董事管 理办法》、《关于上市公司实施员工持股计划试点的指导意见》（以 下简称《指导意见》）、《上海证券交易所上市公司自律监管指引第 1 号—规范运作》（以下简称《监管指引第 1 号》）等法律、法规、 规范性文件以及《公司章程》的有关规定，我们基于独立、认真、谨 慎的立场，现就公司第九届董事会第十八次会议审议的员工持股计划 相关事项发表如下独立意见： （一）公司本期员工持股计划符合《公司法》、《证券法》、《指 导意见》、《监管指引第 1 号》以及其他法律、法规、规范性文件和 《公司章程》的规定，不存在禁止实施员工持股计划的情形。 （二）公司实施本期员工持股计划，有利于完善公司员工和全体 股东的利益共享和风险共担机制，建立健全长效激励机制，充分调动 管理者和员工的积极性和创造性，吸引和保留优秀人才，提升员工的 凝聚力和公司竞争力，促进公司健康、持续发展， ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2023-046 河南太龙药业股份有限公司 关于收到政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 河南太龙药业股份有限公司（以下简称"公司"）及下属子公司 自 2023 年 7 月 1 日至 2023 年 9 月 30 日累计收到政府补助肆佰零玖 万零叁拾玖元捌角陆分（4,090,039.86 元），占公司最近一期经审 计归属于上市公司股东的净利润绝对值的 5.67%。具体明细如下： 单位：元 币种：人民币 序号 获得时间 补助项目 补助类型 补助金额 收款单位 1 2023 年 7 月 13 日 企业房租租金返还 收益相关 739,506.18 新领先（重庆）医 药科技有限公司 2 2023 年 7 月 20 日 重庆市一次性吸纳就业补 贴 收益相关 100,000.00 新领先（重庆）医 药科技有限公司 3 2023 年 7 月 20 日 企业稳岗扩岗补贴 收益相关 15,500.00 桐君堂药业宁波有 限公司 4 2023 ...

证券代码：600222 证券简称：太龙药业 公告编号：2023-045 河南太龙药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 会议召开时间：2023 年 09 月 11 日(星期一) 上午 11:00- 12:00 ● 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络互动 ● 投资者可于 2023 年 09 月 04 日(星期一) 至 09 月 08 日(星 期五)16:00 期间登录上证路演中心网站首页点击"提问预征集"栏目 进行提问， 或 将问题以电子邮件形式发送至 公司邮箱 600222@taloph.com。公司将在说明会上对投资者普遍关注的问题进 行回答。 河南太龙药业股份有限公司（以下简称"公司"）已于 2023 年 8 月 19 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入 地了解公司 2023 年上半年经营成果、 ...

证券代码：600222 证券简称：太龙药业 编号：临 2023-044 河南太龙药业股份有限公司 关于为下属全资公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称：浙江桐君堂中药饮片有限公司（以下简称"中 药饮片公司"）。 本次担保金额及已实际为其提供的担保余额：本次担保金额为 5,000 万元；截至本公告日，河南太龙药业股份有限公司（以下简称 "公司"）及下属子公司已实际为中药饮片公司提供的担保余额为 9,480 万元(含本次)。 本次担保是否有反担保：无 对外担保逾期的累计数量：无 一、担保情况概述 公司（包括子公司）在 2023 年度为子公司在银行申请的综合授信提 供不超过 38,000 万元的连带责任担保，其中对中药饮片公司的预计 担保额度为 13,000 万元。具体内容详见公司分别于 2023 年 4 月 7 日、 2023 年 6 月 22 日在上海证券交易所网站（www.sse.com.cn）披露的 相关公告（公告编号：临 2023-015 号、2023-030 ...

Financial Performance - The company's operating revenue increased by 15.08% year-on-year, primarily due to a surge in demand for heat-clearing and detoxifying drugs, resulting in a significant increase in sales compared to the previous year[19]. - The revenue from the pharmaceutical formulation business grew by 91.04% year-on-year, driven by successful bids in inter-provincial alliance procurement and the continuous enrichment of the traditional Chinese medicine product pipeline[19]. - The net profit attributable to shareholders decreased by 12.9 million yuan, mainly due to increased R&D personnel in research branches and higher investments in high-end formulations and improved new drug projects[19]. - The net cash flow from operating activities decreased by 21.62 million yuan year-on-year, attributed to increased personnel reserves and R&D investments in the pharmaceutical R&D service business[19]. - Basic earnings per share for the reporting period were -0.0677 yuan, compared to -0.0452 yuan in the same period last year[19]. - The diluted earnings per share for the reporting period were -0.0677 yuan, consistent with the basic earnings per share[19]. - The weighted average return on net assets was -2.49%, compared to -1.51% in the same period last year[19]. - The weighted average return on net assets, after deducting non-recurring gains and losses, was -2.62%, compared to -0.91% in the same period last year[19]. - The net profit attributable to shareholders was a loss of ¥38,331,796.75, compared to a loss of ¥25,432,310.28 in the previous year, indicating a worsening financial performance[20]. - The net cash flow from operating activities was a negative ¥88,001,824.00, compared to a negative ¥66,380,836.05 in the same period last year, reflecting increased cash outflows[20]. - The total assets decreased by 5.69% to ¥3,395,367,101.76 from ¥3,600,184,129.95 at the end of the previous year[20]. - The net assets attributable to shareholders decreased by 9.65% to ¥1,418,871,940.83 from ¥1,570,479,281.96 at the end of the previous year[20]. - The company achieved a revenue of 993.91 million yuan in the reporting period, representing a year-on-year growth of 15.08%[42]. - The pharmaceutical formulation business focused on brand building and product structure enhancement, leading to increased market share and sales growth in key products such as Danshen oral liquid and pediatric cough syrup[42]. - The company reported a total comprehensive loss of ¥79,162,210.83 for the first half of 2023, compared to a loss of ¥29,807,692.69 in the previous year[139]. - The company reported a significant increase in sales expenses, which rose to ¥99,791,558.32, up 42.9% from ¥69,823,969.20 in the previous year[134]. Research and Development - Research and development expenses surged by 77.46% to ¥79,750,330.93, up from ¥44,939,144.73, indicating a significant investment in new product development[50]. - The company has 199 ongoing research projects, with 20 submitted for registration, 4 obtaining production registration, and 2 passing consistency evaluations during the reporting period[44]. - The company launched 29 new generic drug projects and 14 improved new drug projects in 2023, with a total of 151 ongoing independent research projects by the end of the reporting period[46]. - The company’s clinical CRO services include comprehensive support for clinical research, from protocol design to data management and statistical analysis[29]. - The company is leveraging its technological platform and investment cooperation to build a comprehensive lifecycle management service system for pharmaceuticals[29]. - The company is actively investing in high-quality projects within the healthcare sector, while remaining vigilant about external economic and regulatory changes that could impact investment returns[71]. Market Position and Strategy - The company operates in the pharmaceutical manufacturing and R&D services sectors, focusing on traditional Chinese medicine and various drug formulations[24]. - The company has over 700 varieties and 1,100 specifications of traditional Chinese medicine pieces, enhancing its competitive edge through value-added services[25]. - The sales model includes a combination of distribution and direct sales, with a marketing network established across more than 30 provinces in China[27]. - The company emphasizes a transparent and safe medication process through technology integration in its traditional Chinese medicine services[28]. - The company has been recognized as one of the "Top 100 Chinese Pharmaceutical Enterprises" and has received multiple honors, including being named a key leading enterprise in Henan Province for 2022-2024[35]. - The company is positioned to benefit from the increasing demand for CRO services, with an expected investment in pharmaceutical R&D in China reaching USD 47.6 billion by 2024, including USD 32.1 billion for clinical stage R&D[34]. Financial Management and Investments - The company completed the establishment of a 400 million yuan pharmaceutical industry fund, with an initial investment of 120 million yuan, to enhance capital operation capabilities[46]. - The company has received 7 domestic patent authorizations during the reporting period, including 3 invention patents[46]. - The company is actively expanding its investment opportunities in the healthcare industry, linking with market investment institutions to explore new growth points[46]. - The company has implemented a comprehensive quality control system in production, adhering to GMP requirements and enhancing operational efficiency[43]. - The company has maintained a 100% compliance rate in external product inspections, ensuring a strong market reputation[40]. Environmental and Social Responsibility - The company is listed as a key pollutant discharge unit in Zhengzhou for 2023, focusing on water environment management[82]. - The company reported a chemical oxygen demand (COD) discharge of 0.91322 tons in the first half of 2023, well below the permitted limit of 100 mg/l[84]. - The company has established an emergency response plan for environmental incidents, updated in May 2022[88]. - The company has implemented a self-monitoring scheme for environmental pollutants, with third-party monitoring confirming compliance with discharge standards[89]. - The company invested 334,600 yuan in poverty alleviation and rural revitalization projects, benefiting 173 individuals through industry and employment support[99]. Corporate Governance and Compliance - The company has committed to not engaging in any competitive activities with Tai Long Pharmaceutical and its subsidiaries during the reporting period[101]. - The company has ensured the independence of Tai Long Pharmaceutical's operations, maintaining separate personnel, assets, finances, and business[102]. - The company will not utilize its shareholder status to seek preferential treatment for itself or its affiliates in business dealings with Tai Long Pharmaceutical[101]. - The company has established a commitment to avoid competition with Tailong Pharmaceutical in any form within or outside China[105]. - The integrity status of the company and its controlling shareholders is good, with no unfulfilled court judgments or significant overdue debts[107]. Shareholder Information - The company had 56,015 common stock shareholders as of the end of the reporting period[118]. - The largest shareholder, Zhengzhou Tairong Industrial Investment Co., Ltd., held 14.37% of the shares, totaling 82,441,168 shares[120]. - Shareholder Wu Lan reduced his holdings by 5,842,200 shares, holding a total of 28,694,296 shares, representing 5.00%[120]. - The company reported a capital increase of 42,067,787.15 CNY from owner contributions during the current period[155]. - The total capital reserve at the end of the period is 750,255,579.20 CNY, which remains stable compared to the previous period[155]. Risk Management - The company faces significant industry policy risks due to the evolving regulatory landscape in the pharmaceutical sector, which has intensified market competition[68]. - Quality risk management is a priority, with the implementation of a comprehensive quality traceability system to ensure drug safety and efficacy throughout the production process[70]. - Research and development risks are acknowledged, with a commitment to enhancing the R&D team and decision-making processes to mitigate potential project delays and failures[71]. - The company is closely monitoring raw material prices and supply risks, which are influenced by various factors, including climate and environmental regulations, to manage operational costs effectively[70].

Group 1: Event Details - The event is scheduled for May 18, 2023, from 16:00 to 17:20 [1] - It will be held online via "全景·路演天下" platform [1] - The theme of the event is "Sincere Communication, Delivering Value" [1] Group 2: Participants - The attendees include General Manager Mr. Luo Jianchao, Board Secretary Ms. Feng Haiyan, and Financial Officer Mr. Zhao Hailin [1] - Participation may be adjusted due to special circumstances [1] Group 3: Company Commitment - The board guarantees the announcement's content is free from false records, misleading statements, or significant omissions [1] - The board takes legal responsibility for the truthfulness, accuracy, and completeness of the content [1]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 560,317,916.01, representing a year-on-year increase of 32.69%[3] - The net profit attributable to shareholders for Q1 2023 was CNY 3,682,566.68, reflecting a growth of 58.07% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 3,452,841.10, an increase of 40.91% year-on-year[3] - The basic earnings per share for Q1 2023 was CNY 0.0065, up by 58.54% from the previous year[3] - The company reported a net profit of CNY 201,783,788.37 for the first quarter of 2023, compared to CNY 186,609,951.83 in the first quarter of 2022, an increase of 8.1%[13] - The net profit for Q1 2023 was approximately ¥3.29 million, compared to ¥2.17 million in Q1 2022, representing a 51.8% increase[17] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 3,572,512,646.95, a decrease of 0.77% from the end of the previous year[4] - The total assets of the company as of March 31, 2023, were CNY 3,572,512,646.95, a slight decrease from CNY 3,600,184,129.95 at the end of 2022[12] - The total liabilities decreased to CNY 1,975,922,301.14 as of March 31, 2023, from CNY 1,986,099,689.13 at the end of 2022, a reduction of 0.6%[13] - The equity attributable to shareholders at the end of Q1 2023 was CNY 1,553,379,373.18, down by 1.09% compared to the end of the previous year[4] Cash Flow and Investments - The net cash flow from operating activities for Q1 2023 was CNY -92,268,340.56, representing a decrease of 39.29% year-on-year[3] - Cash flow from operating activities showed a net outflow of approximately ¥92.27 million in Q1 2023, an improvement from a net outflow of ¥151.97 million in Q1 2022[19] - Investment activities resulted in a net cash outflow of approximately ¥19.64 million in Q1 2023, compared to a net inflow of ¥63.11 million in Q1 2022[19] Shareholder Information - The company had a total of 62,349 common shareholders at the end of the reporting period[6] - The top shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., held 82,441,168 shares, accounting for 14.37% of the total shares[7] Operational Metrics - The company's cash and cash equivalents decreased to CNY 248,462,111.96 as of March 31, 2023, down from CNY 311,383,783.24 at the end of 2022, a decline of 20.1%[11] - Accounts receivable increased to CNY 744,735,581.99 as of March 31, 2023, compared to CNY 709,294,055.62 at the end of 2022, reflecting a growth of 5.0%[11] - The company's inventory as of March 31, 2023, was CNY 433,230,308.30, down from CNY 450,488,977.16 at the end of 2022, a decrease of 3.8%[11] - Non-current assets totaled CNY 1,589,611,259.02 as of March 31, 2023, compared to CNY 1,568,943,854.70 at the end of 2022, an increase of 1.3%[12] Research and Development - The company incurred research and development expenses of approximately ¥24.19 million in Q1 2023, compared to ¥19.58 million in Q1 2022, marking a 23.5% increase[16] Strategic Initiatives - The company established a pharmaceutical industry fund with a total scale of CNY 400 million, with an initial investment of CNY 120 million completed in January 2023[10] - The company is actively linking with market investment institutions and industry resources to expand its upstream and downstream industrial chain[10] Sales Performance - The company reported a significant increase in sales revenue from goods and services, totaling approximately ¥490.86 million in Q1 2023, compared to ¥355.72 million in Q1 2022, reflecting a 38% increase[18] - Total operating costs for Q1 2023 were approximately ¥558.03 million, up from ¥411.80 million in the same period last year, reflecting a 35.5% increase[16]

证券代码：600222 证券简称：太龙药业 公告编号：临 2023-020 河南太龙药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 7 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 10 日下午 15:00-16:30 举行 2022 年度业绩说明会，就投资者关心的问 题进行交流。 一、 说明会类型 本次业绩说明会以视频录播结合网络文字互动的形式召开，公司 河南太龙药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 04 月 28 日(星期五) 至 05 月 09 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 600222@taloph.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 会议召开时间：2023 年 05 月 10 日(星期三) 下午 15: ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,960,694,309.41, representing a 22.20% increase compared to CNY 1,604,516,940.00 in 2021[20]. - The net profit attributable to shareholders of the listed company was a loss of CNY 72,140,214.59, a decrease of 1,303.26% from a profit of CNY 5,995,375.55 in 2021[20]. - The net cash flow from operating activities was a negative CNY 124,405,873.93, down 224.84% from CNY 99,655,159.11 in 2021[21]. - The total assets at the end of 2022 were CNY 3,600,184,129.95, a decrease of 4.85% from CNY 3,783,772,407.22 at the end of 2021[21]. - The net assets attributable to shareholders of the listed company decreased by 5.42% to CNY 1,570,479,281.96 from CNY 1,660,509,428.09 at the end of 2021[21]. - Basic and diluted earnings per share were both -0.1283 yuan, reflecting a significant decrease compared to 0.0107 yuan in the previous year[22]. - The weighted average return on equity was -4.31%, down from 0.37% in the previous year, indicating a decline in profitability[22]. - The gross profit margin decreased by 4.77 percentage points to 24.04% compared to the previous year[66]. - The total revenue for the year 2022 was approximately CNY 1.95 billion, with a gross margin of 24.04%, reflecting a decrease of 4.77 percentage points compared to the previous year[69]. Revenue Segments - The company's operating revenue increased by 22.20% year-on-year, with traditional Chinese medicine segment revenue growing by 29.62% and pharmaceutical formulation revenue increasing by 19.04%[22]. - The revenue from traditional Chinese medicine oral liquids increased by 19.88% year-on-year, reaching approximately CNY 514.4 million, but the gross margin decreased by 5.05 percentage points to 44.29%[69]. - The revenue from Chinese herbal pieces grew by 29.62% year-on-year, totaling approximately CNY 942.4 million, with a stable gross margin of 11.92%[69]. - The revenue from pharmaceutical research and development services remained flat, but the gross margin decreased significantly by 15.31 percentage points to 32.05% due to increased project costs[69]. - The company’s revenue from the cardiovascular system segment was 5,089.73 million RMB, with a gross margin of 83.57%, reflecting a decrease of 3.28% from the previous year[100]. - The company’s revenue from the digestive system segment was 1,473.67 million RMB, with a gross margin of 65.36%, showing a slight increase of 0.56% compared to the previous year[100]. Research and Development - The company is focusing on the development of new products and technologies, although specific details were not disclosed in the report[19]. - The company has 191 research projects, with 43 submitted for registration and 16 obtaining production registration certificates[36]. - The company launched 61 new independent research projects in 2022, with 110 projects still in the pipeline[38]. - The company reported a research and development investment of 6.36% of operating revenue, which is lower than the industry average of 10.00%[106]. - The company’s R&D investment amounted to 6,029.68 million RMB at the end of the reporting period, an increase of 4,457.21 million RMB from the beginning of the period[115]. - The company is actively pursuing the introduction of new traditional Chinese medicine products and enhancing its investment in the development of improved new drugs[23]. - The company has established partnerships with well-known universities and research institutions to enhance its research capabilities in traditional Chinese medicine[101]. Market Strategy and Competitiveness - The company plans to enhance its market competitiveness by increasing sales promotion efforts in key regions and investing in the research of classic Chinese medicine formulas[23]. - The company aims to expand its market presence and enhance customer loyalty through deeper service offerings and strategic partnerships in the pharmaceutical sector[54]. - The company is focusing on diversifying its drug research technology platforms and increasing the number of self-initiated projects, which may impact short-term profitability but is expected to yield results in the future[23]. - The company plans to expand its product range and improve brand influence through differentiated marketing strategies and academic promotion[126]. - The company is committed to strengthening its internal control systems and risk management to ensure sustainable growth[125]. Corporate Governance and Management - The company has conducted 5 shareholder meetings and 13 board meetings during the reporting period, ensuring compliance with governance standards[136]. - The company has implemented a third employee stock ownership plan to enhance performance evaluation and incentive mechanisms for management[137]. - The company has a clear organizational structure that operates independently and effectively, adhering to legal and regulatory requirements[139]. - The company has established a compensation and assessment committee under the board to oversee the remuneration of directors and senior management[153]. - The company emphasizes transparency in its remuneration practices, with clear guidelines for performance evaluation and payment schedules[153]. Environmental Responsibility - The company invested 3.22 million yuan in environmental protection during the reporting period[184]. - The company’s subsidiary, Yu Zhong Pharmaceutical Factory, was listed as a key pollutant discharge unit in Zhengzhou for 2022[185]. - The wastewater treatment facility at the company can process 1,000 tons of wastewater daily, utilizing a series of advanced treatment processes to ensure compliance with discharge standards[188]. - The company reported that all major pollutants, including SO2 and nitrogen oxides, from both its facilities met the emission standards[190]. - The company has received its pollution discharge permit as of July 2020, in compliance with national regulations[191]. Social Responsibility - Total charitable contributions amounted to 260,400 RMB, including donations to various charitable organizations and educational funds[200]. - The company donated 100,000 RMB to the Henan Charity Federation and 20,000 RMB to the Tonglu County Charity Federation[200]. - During the pandemic, the company provided anti-epidemic supplies to local communities, demonstrating its commitment to social responsibility[200].